Drug firm Torrent Pharmaceuticals Monday reported a consolidated net loss of Rs 152 crore for the quarter ended March 31, 2019, mainly on account of exceptional items.
The company had posted a net profit of Rs 228 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a filing to the BSE.
The company's consolidated revenue from operations stood at Rs 1,856 crore for the quarter under consideration. It was Rs 1,708 crore for the same period year ago.
Net loss of Rs 152 crore for the fourth quarter is on account of exceptional items of Rs 357 crore and lower hedging gains, the company said.
Out of Rs 357 crore exceptional items, Rs 217 crore pertains to impairment provision of certain intangible assets under development and goodwill recognised with respect to the acquisition of Bio-Pharm Inc and Rs 140 crore is in relation to product recalls made during the current year, it added.
For the fiscal year ended March 2019, the company posted a net profit of Rs 436 crore as against Rs 678 crore for the previous fiscal year.
The company's consolidated revenue from operations for the fiscal year ended March 2019 stood at Rs 7,673 crore as against Rs 5,950 crore for 2017-18.
The company's board has declared a final dividend of Rs 4 per equity share, Torrent Pharmaceuticals said.
Shares Of Torrent Pharmaceuticals Monday closed at Rs 1,655.70 per scrip on the BSE, up 0.53 per cent from its previous close.